Phase II study of S-1 plus either irinotecan or docetaxel for non-small cell lung cancer patients treated with more than three lines of treatment
- Dal Yong Kim
- , Dae Ho Lee
- , Sun Joo Jang
- , Sang We Kim
- , Cheolwon Suh
- , Jung Shin Lee
- University of Ulsan
Research output: Contribution to journal › Article › peer-review
2
Scopus
citations